Structure-activity Relationship of Pharmacophores and Toxicophores: the Need for Clinical Strategy

Overview

Journal Daru

Specialty Pharmacology

Date 2024 Jun 27

PMID 38935265

Authors

Saganuwan Alhaji Saganuwan

Affiliations

Soon will be listed here.

Abstract

Objectives: Sometimes clinical efficacy and potential risk of therapeutic and toxic agents are difficult to predict over a long period of time. Hence there is need for literature search with a view to assessing cause of toxicity and less efficacy of drugs used in clinical practice.

Method: Hence literatures were searched for physicochemical properties, chemical formulas, molecular masses, pH values, ionization, receptor type, agonist and antagonist, therapeutic, toxic and structure-activity relationship of chemical compounds with pharmacophore and toxicophore, with a view to identifying high efficacious and relative low toxic agents. Inclusion criteria were manuscripts published on PubMed, Scopus, Web of Science, PubMed Central, Google Scholar among others, between 1960 and 2023. Keywords such as pharmacophore, toxicophore, structure-activity-relationship and disease where also searched. The exclusion criteria were the chemicals that lack pharmacophore, toxicophore and manuscripts published before 1960.

Results: Findings have shown that pharmacophore and toxicophore functional groups determine clinical efficacy and safety of therapeutics, but if they overlap therapeutic and toxicity effects go concurrently. Hence the functional groups, dose, co-administration and concentration of drugs at receptor, drug-receptor binding and duration of receptor binding are the determining factors of pharmacophore and toxicophore activity. Molecular mass, chemical configuration, pH value, receptor affinity and binding capacity, multiple pharmacophores, hydrophilic/lipophilic nature of the chemical contribute greatly to functionality of pharmacophore and toxicophore.

Conclusion: Daily single therapy, avoidance of reversible pharmacology, drugs with covalent adduct, maintenance of therapeutic dose, and the use of multiple pharmacophores for terminal diseases will minimize toxicity and improve efficacy.

References

Gopal K, Wu C, Moore E, Gross G . Assessment of styrene oxide neurotoxicity using in vitro auditory cortex networks. ISRN Otolaryngol. 2013; 2011:204804. PMC: 3658808. DOI: 10.5402/2011/204804. View

Roca-Vinardell A, Berrocoso E, Llorca-Torralba M, Garcia-Partida J, Gibert-Rahola J, Mico J . Involvement of 5-HT receptors in the antinociceptive effect of paracetamol in the rat formalin test. Neurobiol Pain. 2019; 3:15-21. PMC: 6550097. DOI: 10.1016/j.ynpai.2018.01.004. View

Asra R, Jones A . Green electrosynthesis of drug metabolites. Toxicol Res (Camb). 2023; 12(2):150-177. PMC: 10141794. DOI: 10.1093/toxres/tfad009. View

Thompson W, Hornby B, Manuel R, Bradley E, Laux J, Carr J . A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genet Med. 2020; 23(3):471-478. PMC: 7935714. DOI: 10.1038/s41436-020-01006-8. View

Che J, Wang Z, Sheng H, Huang F, Dong X, Hu Y . Ligand-based pharmacophore model for the discovery of novel CXCR2 antagonists as anti-cancer metastatic agents. R Soc Open Sci. 2018; 5(7):180176. PMC: 6083693. DOI: 10.1098/rsos.180176. View

Chou W, Chen Q, Yuan L, Cheng Y, He C, Monteiro-Riviere N . An artificial intelligence-assisted physiologically-based pharmacokinetic model to predict nanoparticle delivery to tumors in mice. J Control Release. 2023; 361:53-63. PMC: 11008607. DOI: 10.1016/j.jconrel.2023.07.040. View

Dror O, Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson H . Novel approach for efficient pharmacophore-based virtual screening: method and applications. J Chem Inf Model. 2009; 49(10):2333-43. PMC: 2767445. DOI: 10.1021/ci900263d. View

Nisijima K, Yoshino T, Yui K, Katoh S . Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Res. 2001; 890(1):23-31. DOI: 10.1016/s0006-8993(00)03020-1. View

Kalgutkar A, Fate G, Didiuk M, Bauman J . Toxicophores, reactive metabolites and drug safety: when is it a cause for concern?. Expert Rev Clin Pharmacol. 2014; 1(4):515-31. DOI: 10.1586/17512433.1.4.515. View

10.

Chang C, Ekins S, Bahadduri P, Swaan P . Pharmacophore-based discovery of ligands for drug transporters. Adv Drug Deliv Rev. 2006; 58(12-13):1431-50. PMC: 1773055. DOI: 10.1016/j.addr.2006.09.006. View

11.

Saganuwan S . Chemistry and Effects of Brainstem Acting Drugs. Cent Nerv Syst Agents Med Chem. 2019; 19(3):180-186. DOI: 10.2174/1871524919666190620164355. View

12.

Bond J, Brimblecombe R, CODNER R . Biological assay of cephalosporin C. J Gen Microbiol. 1962; 27:11-9. DOI: 10.1099/00221287-27-1-11. View

13.

Opo F, Rahman M, Ahammad F, Ahmed I, Bhuiyan M, Asiri A . Structure based pharmacophore modeling, virtual screening, molecular docking and ADMET approaches for identification of natural anti-cancer agents targeting XIAP protein. Sci Rep. 2021; 11(1):4049. PMC: 7892887. DOI: 10.1038/s41598-021-83626-x. View

14.

Toms L, McQuay H, Derry S, Moore R . Single dose oral paracetamol (acetaminophen) for postoperative pain in adults. Cochrane Database Syst Rev. 2008; (4):CD004602. PMC: 4163965. DOI: 10.1002/14651858.CD004602.pub2. View

15.

Brown D, Shotton E . Diamond: shedding light on structure-based drug discovery. Philos Trans A Math Phys Eng Sci. 2015; 373(2036). DOI: 10.1098/rsta.2014.0468. View

16.

Kohlbacher S, Schmid M, Seidel T, Langer T . Applications of the Novel Quantitative Pharmacophore Activity Relationship Method QPhAR in Virtual Screening and Lead-Optimisation. Pharmaceuticals (Basel). 2022; 15(9). PMC: 9504690. DOI: 10.3390/ph15091122. View

17.

Wang S, Dong G, Sheng C . Structural simplification: an efficient strategy in lead optimization. Acta Pharm Sin B. 2019; 9(5):880-901. PMC: 6804494. DOI: 10.1016/j.apsb.2019.05.004. View

18.

Poli G, Dimmito M, Mollica A, Zengin G, Benyhe S, Zador F . Discovery of Novel µ-Opioid Receptor Inverse Agonist from a Combinatorial Library of Tetrapeptides through Structure-Based Virtual Screening. Molecules. 2019; 24(21). PMC: 6865014. DOI: 10.3390/molecules24213872. View

19.

Ma L, Zhou Y, Yang D, Wang M, Lu W, Jin J . Synthesis of Hydantoin Androgen Receptor Antagonists and Study on Their Antagonistic Activity. Molecules. 2022; 27(18). PMC: 9505067. DOI: 10.3390/molecules27185867. View

20.

Keck T, John W, Czoty P, Nader M, Newman A . Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis. J Med Chem. 2015; 58(14):5361-80. PMC: 4516313. DOI: 10.1021/jm501512b. View